You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海醫藥(02607.HK)注射用頭孢曲松鈉及注射用蘭索拉唑通過仿製藥一致性評價
格隆匯 06-23 17:43

格隆匯6月23日丨上海醫藥(02607.HK)公佈,近日,公司控股子公司上海上藥新亞藥業有限公司分別收到國家藥品監督管理局頒發的關於注射用頭孢曲松鈉(4個規格)及注射用蘭索拉唑的《藥品補充申請批准通知書》,上述藥品通過仿製藥一致性評價。

截至本公吿日,公司針對注射用頭孢曲松鈉的一致性評價已投入研發費用約人民幣1,027萬元。截至本公吿日,中國境內注射用頭孢曲松鈉的主要生產廠家為上海羅氏製藥有限公司、齊魯製藥有限公司、湖南科倫製藥有限公司等。IQVIA數據庫顯示,2020年注射用頭孢曲松鈉醫院採購金額為人民幣249,334萬元。2020年,上藥新亞的注射用頭孢曲松鈉銷售收入為人民幣8,078萬元。

此外,截至本公吿日,針對注射用蘭索拉唑的一致性評價已投入研發費用約人民幣498萬元(根據代理銷售合同安排,該筆研發費用由合作方承擔)。截至本公吿日,中國境內注射用蘭索拉唑的主要生產廠家為山東羅欣藥業集團股份有限公司、江蘇奧賽康藥業有限公司等。IQVIA數據庫顯示,2020年注射用蘭索拉唑醫院採購金額為人民幣176,639萬元。2020年,上藥新亞的注射用蘭索拉唑銷售收入為人民幣5,080萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account